Kiniksa Pharmaceuticals International Plc. Receivables

As of the most recent data (March 2026), KNSA shows a receivables of $23M. That compares with $40M in the prior-year period — down 42.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KNSA's receivables is now $23M (was $40M) — a 42.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Kiniksa Pharmaceuticals International Plc. is outperforming or lagging.

Tracking KNSA's receivables over time shows whether Kiniksa Pharmaceuticals International Plc. is scaling, shrinking, or reshaping that part of the business. The current reading is $23M That compares with $40M in the prior-year period — down 42.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Kiniksa Pharmaceuticals International Plc.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $23M) with ownership activity and broader fundamentals.

Kiniksa Pharmaceuticals International Plc.'s receivables is $23M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.